25,729 articles
Methyltestosterone
Methyltestosterone, sold under brand names including Testred and Methitest, is a synthetic oral anabolic-androgenic steroid, first synthesized in 1935, used for testosterone replacement in men and delayed puberty.
Methylthiouracil
Methylthiouracil is a thionamide antithyroid drug introduced in the mid-1940s to treat hyperthyroidism by blocking thyroid hormone synthesis, but withdrawn in most countries because of adverse reactions.
Methyprylon
Methyprylon (Noludar, Rol-6463), a piperidinedione non-barbiturate sedative-hypnotic once marketed by Hoffmann-La Roche for insomnia; FDA-approved 1955, discontinued, GABA_A-acting, now not recommended.
Metipranolol
Metipranolol (OptiPranolol, Trimepranol) is a non-selective beta-blocker used as 0.3% eye drops twice daily for open-angle glaucoma and ocular hypertension; associated with granulomatous anterior uveitis and UK withdrawal.
Metoclopramide
Metoclopramide (Maxolon, Reglan) is a benzamide D2 antagonist, 5-HT4 agonist, and 5-HT3 antagonist anti-emetic and prokinetic, discovered in the 1950s from procainamide, limited by tardive dyskinesia risk and EU 5-day dosing caps.
Metoidioplasty
Metoidioplasty is a gender-affirming surgery, also called clitoral release, that reconstructs a testosterone-enlarged clitoris into a small neophallus, usually one-stage, enabling standing urination and preserved sensation but not penetrative intercourse.
Metolazone
Metolazone (Zaroxolyn, Mykrox) is a long-acting quinazoline thiazide-type diuretic approved by the FDA in 1973 for edema in heart failure and renal disease and for hypertension; it works even at GFR below 20 mL/min.
Metopic ridge
Metopic ridge: a benign midline forehead ridge from normal thickening after the metopic suture fuses at 3-9 months; distinguished from metopic craniosynostosis (trigonocephaly), which is surgical.
Metoprolol
Metoprolol (Lopressor, Toprol-XL) is a beta-1 selective blocker marketed as tartrate and extended-release succinate salts; used for hypertension, angina, arrhythmias, post-infarction, and HFrEF, where MERIT-HF showed mortality reduction.
Metreleptin
Metreleptin (Myalept, Myalepta) is a recombinant human leptin analog injected daily for complications of leptin deficiency in lipodystrophy. FDA approved 2014 for generalized lipodystrophy; EU 2018; lowers HbA1c and triglycerides; REMS-restricted.
Metrizamide
Metrizamide (brand name Amipaque) is a non-ionic, water-soluble iodinated x-ray contrast medium, the first low-osmolar agent in clinical use, marketed in 1972 by Nyegaard of Oslo and now discontinued.
Metrizoic acid
Metrizoic acid (metrizoate; Isopaque, Triosil) is an ionic monomeric triiodobenzoate X-ray contrast medium, high-osmolar at 2,100 mOsm/kg, historically used in urography and angiography; FDA approval discontinued.
METROCLIN trial
METROCLIN (NCT07392047) is a Phase 4 randomized controlled trial comparing topical metronidazole 2% gel versus clindamycin 1% gel for moderate acne vulgaris in 60 adults aged 18-35 at Jinnah Postgraduate Medical Centre, Karachi, starting February 2026.
Metronidazole
Metronidazole (Flagyl) is a synthetic 5-nitroimidazole antibiotic and antiprotozoal drug developed at Rhône-Poulenc in 1957 from azomycin, used against obligate anaerobes, trichomoniasis, amebiasis, and giardiasis, with an 8-hour half-life and alcohol interaction.
Metronomic chemotherapy
Metronomic chemotherapy is a way of giving cancer drugs continuously at low, largely non-toxic doses with no prolonged drug-free breaks, in contrast to conventional maximum-tolerated-dose cycles with rest periods.
Metroplasty
Metroplasty is a surgical procedure, now performed almost entirely through the hysteroscope, that corrects congenital uterine malformations, above all the septate uterus, to improve reproductive outcomes.
METSYND trial
METSYND (NCT03019796) is a completed Early Phase 1 randomized trial at the University of Castilla-La Mancha, Toledo, Spain, testing exercise training (HIIT and other modalities) with and without habitual medications in adults with metabolic syndrome.
METTLE trial
METTLE (NCT06405971) is a Chinese randomized, double-blind, placebo-controlled trial testing 250 mg metformin twice daily versus placebo in 60 patients with unruptured vertebrobasilar dissecting aneurysms, using 3D wall enhancement volume rate on HR-VWI at 6 months as the primary outcome.
Metyrapone
Metyrapone, sold as Metopirone, is a drug that inhibits cortisol synthesis in the adrenal cortex, used diagnostically and to treat Cushing's syndrome in many countries.
Mevonlerbart
Mevonlerbart (REGN1909) is a fully human monoclonal antibody from Regeneron that binds Fel d 1, the dominant cat allergen, and is in Phase 3 development for cat allergy.
Mewing (orthotropics)
Mewing: tongue-on-palate posture technique from John Mew's orthotropics, viral on social media for jawline reshaping; orthodontic bodies find no scientific evidence and cite risks.
Mexico APL study
Mexico APL study (NCT04562818), a retrospective multicenter study by Instituto Nacional de Cancerologia de Mexico of 360 acute promyelocytic leukemia patients treated 2007-2017 with anthracycline plus ATRA, reporting 84% overall survival at 150 months.
Mezigdomide
Mezigdomide (CC-92480, BMS-986348) is an oral cereblon E3 ligase modulator (CELMoD) degrading Ikaros/Aiolos, investigated for relapsed/refractory multiple myeloma; SUCCESSOR-2 showed PFS 18.0 vs 8.3 months, FDA NDA accepted 2026.
Mezlocillin
Mezlocillin (Mezlin, Baypen, BAY-F-1353) is a semisynthetic ureidopenicillin beta-lactam antibiotic developed by Bayer, FDA approved in 1981, given parenterally for serious gram-negative infections, and discontinued in the U.S.
MGAP-GAP study
MGAP-GAP study (NCT06732791): prospective observational cohort at Al-Kadhimiya Teaching Hospital, Baghdad, comparing MGAP and GAP trauma scores for predicting mortality, ICU admission, and surgery in multiple trauma patients; 522 participants, 2025-2027, Al-Nahrain University.
MGAT2-CDG
MGAT2-CDG (formerly CDG-IIa, Alkuraya syndrome) is an autosomal recessive congenital disorder of glycosylation caused by MGAT2 loss-of-function mutations at 14q21, causing facial dysmorphism, seizures, developmental delay, and bleeding tendency.
MGM-16
MGM-16, or 9-fluoro-dihydro-7-hydroxymitragynine, is a semi-synthetic fluorinated kratom-alkaloid derivative and full μ/δ opioid agonist reported in 2014; potent in mouse pain models, never studied in humans, U.S. Schedule I since August 26, 2026.
MGMT promoter methylation testing
MGMT promoter methylation testing is a clinical biomarker assay that detects methylation of the MGMT gene promoter, used mainly in glioblastoma to predict benefit from temozolomide.
MHSU trial
MHSU trial (NCT05865873): Hawassa University cluster randomized controlled trial in Sidama, Ethiopia, testing women's-group audio health education; it raised antenatal care and facility delivery use but not postnatal care.
MHTS-ONSD trial
MHTS-ONSD (NCT07786324) is a not-yet-recruiting Assiut University trial comparing 3% hypertonic saline with 20% mannitol for raised intracranial pressure in severe traumatic brain injury, measured by serial optic nerve sheath diameter ultrasound at 2, 6, and 24 hours in 100 adults.